Establishment and progress of cell culture study model of hepatitis C virus

doi:10.3877/cma.j.issn.1674-1358.2016.06.002

Abstract

Abstract:

Hepatitis C virus could lead to serious liver diseases. During the last decade, many progress of HCV in vitro studies had been achieved. Among which, HCV cell culture study model was an important system for pathogenic mechanism researches, antiviral drug screening and also vaccine researches. This paper reviewed the development course, especially the main phases, key application fields, and also supply more understanding on this field.

Key words: Hepatitis C virus, Cell culture model

Qi Wang, Wen Xie. Establishment and progress of cell culture study model of hepatitis C virus[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(06): 654-658.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.06.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I06/654

References 52

1	Global burden of disease (GBD) for hepatitis C[J]. J Clin Pharmacol,2004,44(1):20-29.
2	陈园生，李黎，崔富强, 等. 中国丙型肝炎血清流行病学研究[J]. 中华流行病学杂志,2011,32(9):888-891.
3	Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science,1999,285(5424):110-113.
4	Ikeda M, Yi M, Li K, et al. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells[J]. J Virol,2002,76(6):2997-3006.
5	Gates AT, Sarisky RT, Gu B. Sequence requirements for the development of a chimeric HCV replicon system[J]. Virus Res,2004,100(2):213-222.
6	Qi X, Bae A, Liu S, et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates[J]. Antiviral Res,2009,81(2):166-173.
7	Gieseler RK, Marquitan G, Schlattjan M, et al. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C[J]. J Viral Hepat,2011,18(11):760-767.
8	Yon C, Viswanathan P, Rossignol JF, et al. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells[J]. Antiviral Res,2011,91(3):233-240.
9	Panigrahi R, Chandra PK, Ferraris P, et al. Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1[J]. J Virol,2015,89(1):626-642.
10	Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture[J]. Curr Opin Microbiol,2006,9(4):416-422.
11	Yanagi M, Purcell RH, Emerson SU, et al. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee[J]. Proc Natl Acad Sci USA,1997,94(16):8738-8743.
12	Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication[J]. J Virol,2002,76(24):13001-13014.
13	Peng B, Yu M, Xu S, et al. Development of robust hepatitis C virus genotype 4 subgenomic replicons[J]. Gastroenterology,2013,144(1):59-61. e6.
14	Steinmann E, Pietschmann T. Cell culture systems for hepatitis C virus[J]. Curr Top Microbiol Immunol,2013,369:17-48.
15	Appel N, Herian U, Bartenschlager R. Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A[J]. J Virol,2005,79(2):896-909.
16	Blight KJ, McKeating JA, Marcotrigiano J, et al. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture[J]. J Virol,2003,77(5):3181-3190.
17	Liu S, Nelson CA, Xiao L, et al. Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase[J]. Antiviral Res,2011,89(1):54-63.
18	Wu Y, Liao Q, Yang R, et al. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication[J]. Virus Res,2011,155(2):406-414.
19	Li YP, Ramirez S, Gottwein JM, et al. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains[J]. Proc Natl Acad Sci USA,2012,109(18):E1101-E1110.
20	Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes[J]. J Exp Med,2003,197(5):633-642.
21	Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles[J]. Proc Natl Acad Sci USA,2003,100(12):7271-7276.
22	Cai Z, Zhang C, Chang KS, et al. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells[J]. J Virol,2005,79(22):13963-13973.
23	Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry[J]. Curr Top Microbiol Immunol,2013,369:87-112.
24	Kato T, Furusaka A, Miyamoto M, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient[J]. J Med Virol,2001,64(3):334-339.
25	Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J]. Nat Med,2005,11(7):791-796.
26	Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro[J]. Proc Natl Acad Sci USA,2005,102(26):9294-9299.
27	Date T, Kato T, Miyamoto M, et al. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells[J]. J Biol Chem,2004,279(21):22371-22376.
28	Kato T, Date T, Miyamoto M, et al. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon[J]. J Virol,2005,79(1):592-596.
29	Gorzin AA, Ramsland PA, Tachedjian G, et al. Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle[J]. J Viral Hepat,2012,19(3):189-198.
30	Chan K, Robinson M, Yang H, et al. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors[J]. Antiviral Res,2013,98(1):85-92.
31	Jiang J, Luo G. Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus[J]. J Virol,2012,86(17):8987-8997.
32	Han Q, Xu C, Wu C, et al. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus[J]. Virus Res,2009,145(1):63-73.
33	Liu S, Xiao L, Nelson C, et al. A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses[J]. PLoS One,2012,7(9):e44965.
34	Tao W, Xu C, Ding Q, et al. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles[J]. Virology,2009,395(1):67-76.
35	Grove J, Nielsen S, Zhong J, et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies[J]. J Virol,2008,82(24):12020-12029.
36	Kim CS, Keum SJ, Jang SK. Generation of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature[J]. PLoS One,2011,6(8):e22808.
37	Brohm C, Steinmann E, Friesland M, et al. Characterization of determinants important for hepatitis C virus p7 function in morphogenesis by using trans-complementation[J]. J Virol,2009,83(22):11682-11693.
38	Lohmann V, Hoffmann S, Herian U, et al. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture[J]. J Virol,2003,77(5):3007-3019.
39	Huang Y, Staschke K, De Francesco R, et al. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication[J]. Virology,2007,364(1):1-9.
40	Lim YS, Hwang SB. Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type Ⅲalpha and regulates viral propagation[J]. J Biol Chem,2011,286(13):11290-11298.
41	Kaul A, Woerz I, Meuleman P, et al. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant[J]. J Virol,2007,81(23):13168-13179.
42	Kaul A, Stauffer S, Berger C, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics[J]. PLoS Pathog,2009,5(8):e1000546.
43	Yamamoto M, Sakamoto N, Nakamura T, et al. Studies on virus kinetics using infectious fluorescence-tagged hepatitis C virus cell culture[J]. Hepatol Res,2011,41(3):258-269.
44	Shrivastava S, Devhare P, Sujijantarat N, et al. Knockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway[J]. J Virol,2015,90(3):1387-1396.
45	Haqshenas G, Mackenzie JM, Dong X, et al. Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome[J]. J Gen Virol,2007,88(Pt 1):134-142.
46	Clarke D, Griffin S, Beales L, et al. Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro[J]. J Biol Chem,2006,281(48):37057-37068.
47	Chandra PK, Gunduz F, Hazari S, et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis[J]. PLoS One,2014,9(9):e108616.
48	Chandra PK, Bao L, Song K, et al. HCV infection selectively impairs type I but not type Ⅲ IFN signaling[J]. Am J Pathol,2014,184(1):214-229.
49	Liu S, Chen R, Hagedorn CH. Direct visualization of hepatitis C virus-infected Huh7.5 cells with a high titre of infectious chimeric JFH1-EGFP reporter virus in three-dimensional Matrigel cell cultures[J]. J Gen Virol,2014,95(Pt 2):423-433.
50	Meyer K, Kwon YC, Liu S, et al. Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection[J]. Sci Rep,2015,5:9012.
51	Ramirez S, Mikkelsen LS, Gottwein JM, et al. Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir[J]. Gastroenterology,2016,151(5):973-985.
52	Liu F, Shimakami T, Murai K, et al. Efficient Suppression of hepatitis C virus replication by combination treatment with miR-122 antagonism and direct-acting antivirals in cell culture systems[J]. Sci Rep,2016,6:30939.

[1]	Yunyu Zhao, Caini He, Peigen Gao, Ying Liu, Leiqing Yao, Rong Gao, Jiashu Liu, Fu Wei, Shen Li, Longfei Zhu, Zhengxiao Li, Fanpu Ji. A retrospective study of 6 patients with hepatitis C virus associated cutaneous manifestations treated with direct-acting antivirals [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(06): 507-512.
[2]	Fengcong Zhao, Aizezi Mahemure, Nusilaiti, Yongping Zhang, Jun Cheng. Clinical features and treatment of 167 patients with hepatitis C virus and human immunodeficiency virus coinfection in a hospital from 2008 to 2018 [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(06): 453-460.
[3]	Lan Bu, Xuan Bai. Efficacy and safety of ledipasvir/sofosbuvir in liver fibrosis patients with hepatitis C virus and human immunodeficiency virus coinfection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(05): 488-493.
[4]	Chaoqun Huang, Fuxiang Wang. Genotype of HCV genes in a tertiary hospital in Harbin [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(05): 483-489.
[5]	Bo Sheng, Meng Xu, Lan Li, Zixuan Yang, Yunxia Ji, Rui Wang, Hao Wu, Hongquan Cui. Clinical analysis of HIV/AIDS patients with hepatitis B, hepatitis C virus infection and blood indicators [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(04): 377-381.
[6]	Xin Zhang, Maorong Wang, Zhiguo Yang, Changlun He, Yunhua Sui, Min Shen, Yan Cheng, Jing Xu, Yunfeng Sheng, Yuan Dong, Yue Zhang, Yaofeng Wang, Jun Shao, Xin Li, Xiaofeng Zhang. Curative effect of ribavirin combined with pegylated (Peg) interferon (IFN) α-2a, PegIFN-α-2b and IFN-α-2b for patients with chronic hepatitis C [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(02): 134-140.
[7]	Ying Zhang, Xuejun Leng, Xuebing Yan. Interaction between anti-HCV direct anti-viral agents and other drugs [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(02): 105-110.
[8]	Danhui Sun, Xuebing Yan. Research progress of the related resistance mutations of direct-acting antiviral agents for HCV infection treatment [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(05): 534-540.
[9]	Na Li, Dan Wang. Progress in research on hepatitis C virus infection in kidney transplant recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 58-62.
[10]	Chenchen Zhu, Fei Han, Zhangfei Shou. Kidney transplantation from HCV-positive donors: a single-center experience [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 47-53.
[11]	Chinese Lung Transplant Alliance, National Lung Transplantation Quality Management and Control Center, National Lung Transplantation Data Center. Summary of 2019 Annual Conference of International Society of Heart and Lung Transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2019, 13(03): 195-200.
[12]	Sangwangmu Ge, Zhongfei Chang, Yalu Du, Yunqi Liu, Yaxin Liu, Modi Li. The analysis of epidemiological characteristics of primary liver cancer in our hospital from 2001 to 2017 [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(03): 206-210.
[13]	Qiujing Wei, Yutong Jiang, Jiewen Xie, Zhongming Wu, Liudan Tu, Jieruo Gu. Clinical significance of serum antinuclear antibody profiling in patients with viral hepatitis [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2020, 08(02): 100-104.
[14]	Yanmei Ge, Suyi Fan, Yaoyao Wang, Yuan Mao, Peng Cao. The study on the stability of commercial quality control products of Hepatitis C virus RNA [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2017, 05(02): 103-106.
[15]	Yongping Zhang, Lan Liu, Yanjun Zhang. Expression of monocytes pro-inflammatory cytokines and anti-inflammatory factors in patients with hepatitisC cirrhosis [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2020, 06(01): 23-27.

Please choose a citation manager

Content to export